Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III randomized, double-blind, placebo-controlled trial of BGM0504 injection for weight management in overweight or obese non-diabetic adults in China
CTR20243983Phase 3Completed
- Sponsor
- Borray New Creation Biopharmaceutical Technology
- Start
- Oct 2024
- Modality
- Peptides
- Countries
- 1
01
Overview
A Phase 3 trial of BGM0504 in obesity, Overweight, sponsored by Borray New Creation Biopharmaceutical Technology. Started Oct 2024; status: completed.
02
Drugs
BGM0504
03
Conditions
obesityOverweight
Beyond the preview
Go deeper on CTR20243983.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20243983.